Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Hepatitis C infection is associated with an increased risk of non-Hodgkin lymphoma

Hepatitis C infection is associated with an increased risk of non-Hodgkin lymphoma (malignancy involving lymphatic tissue) of 20 percent to 30 percent, and a three-fold increase in the risk of another type of lymphoma, according to a study in the May 9 issue of JAMA.

9 May 2007

Abbott seeks U.S. and E.U. approvals for Humira as a treatment for juvenile rheumatoid arthritis

Abbott has announced it has simultaneously submitted a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMEA) seeking approval to market HUMIRA (adalimumab) as a treatment for juvenile rheumatoid arthritis (JRA) in the U.S. and juvenile idiopathic arthritis (JIA) in the European Union (EU).

9 May 2007

PET-CT is better for early detection of muscular lymphoma than CT alone

For the study, PET-CT was used to image 305 patients with lymphoma. Twelve of these patients had muscular involvement in which 10 were biopsy proven and two were proven by imaging follow-up.

8 May 2007

Hepatitis C increases risk for non-Hodgkin's lymphoma

Researchers in the U.S. have found that an infection with the hepatitis C virus increases the risk of a person developing non-Hodgkin's lymphoma.

8 May 2007

Rituximab reduces disease activity in multiple sclerosis

A new drug under investigation shows a reduction in disease activity in multiple sclerosis (MS), according to two studies that will be presented at the American Academy of Neurology's 59th Annual Meeting in Boston. The drug reduced disease activity as indicated by MRI scans.

2 May 2007

World's first microRNA knockout mouse

A role for a microRNA in the immune system has been shown by study of one of the world's first microRNA knockout mouse, reported in Science.

27 Apr 2007

Johns Hopkins team stops form of blood cancer in its tracks

A Johns Hopkins team has stopped in its tracks a form of blood cancer in mice by engineering and inactivating an enzyme, telomerase, thereby shortening the ends of chromosomes, called telomeres.

26 Apr 2007

FDA panel recommends new HIV drug Maraviroc

Approval is expected to be granted in the United States for a new drug to treat HIV infections.

24 Apr 2007

Naturally occurring compound found in many fruits and vegetables as well as red wine, selectively kills leukemia cells

These findings, which were published online March 20 in the Journal of Biological Chemistry and will be in press on May 4, offer hope for a more selective, less toxic therapy for leukemia.

24 Apr 2007

New drug Maraviroc an alternative in the fight against HIV

An experimental AIDS drug appears to offer an alternative drug in the fight against HIV.

22 Apr 2007

M. D. Anderson wins $8.3-million to research environmental causes of major diseases

An $8.3-million federal grant to The University of Texas M. D. Anderson Cancer Center Science Park - Research Division addresses the complex interplay between such varied factors as genetics, diet, and environmental exposure to toxins that cause cancer, asthma, diabetes, cardiovascular and other diseases.

21 Apr 2007

Aspirin use linked to moderate drop in cancer risk

A new American Cancer Society study finds men and women who used adult-strength aspirin (325 mg or more) daily for five or more years had an approximately 15 percent lower rate of developing any cancer than those who did not use aspirin.

20 Apr 2007

Novel targeted therapy effectively treats acute leukemia

Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have found that a novel targeted therapy effectively treats acute leukemia in animal models by preventing cancer cells from being purged of damaged proteins.

20 Apr 2007

New method predicts hip joint decay from chemotherapy

Investigators at St. Jude Children's Research Hospital say they have found the best way for predicting when patients will need future surgery to repair hip joints that have deteriorated because of pediatric leukemia or lymphoma treatment.

20 Apr 2007

Novel method to expand the number of immune system "natural killer" cells from blood cells outside the body

Researchers at the Kimmel Cancer Center at Jefferson in Philadelphia have devised a novel method to expand the number of immune system "natural killer (NK)" cells from blood cells outside the body.

19 Apr 2007

Factors that dictate risk of developing primary or secondary cancer

Every day, people make assumptions, educated and not, about their risk for developing cancer.

18 Apr 2007

Aspirin may modestly reduce cancer risk

A daily dose of adult-strength aspirin may modestly reduce cancer risk in populations with high rates of colorectal, prostate, and breast cancer if taken for at least five years.

18 Apr 2007

Vitamin D: sunshine, diet and supplements - cancer prevention and therapy

Vitamin D deficiency is common and cancer risk is higher among those individuals with low vitamin D levels, according to an analysis of research which will be presented at a symposium by Donald L.

17 Apr 2007

Anti-anemia drug darbepoetin alfa no better than placebo for cancer patients

Results from a phase III drug trial indicate that an anti-anemia drug did not significantly decrease the need for blood transfusions in patients not on chemotherapy, and decreased overall patient survival when compared to placebo, according to researchers from the UCLA Medical Center at the 2007 Annual Meeting of the American Association for Cancer Research.

17 Apr 2007